Sunshine Biopharma stock rises after Health Canada approval for Domperidone
PositiveFinancial Markets

Sunshine Biopharma's stock has seen a significant rise following Health Canada's approval of its drug, Domperidone. This approval is a major milestone for the company, as it opens the door for the drug to be marketed and sold in Canada, potentially leading to increased revenue and growth opportunities. Investors are optimistic about the future, as this approval not only validates the company's efforts but also enhances its credibility in the biopharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System






